Sistema de Salut de Catalunya
Institut Català de la Salut
[Takekuma M] Department of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan. [Nishio S] Department of Obstetrics and Gynecology, Kurume University Hospital, Kurume, Japan. [Yamaguchi S] Department of Gynecology, Hyogo Cancer Center, Akashi, Japan. [Yunokawa M] Department of Gynecology, Cancer Institute Hospital of JFCR, Tokyo, Japan. [Nishio H] Department of Obstetrics and Gynecology, Keio University Hospital, Tokyo, Japan. [Nishino K] Department of Obstetrics and Gynecology, Niigata University Medical & Dental Hospital, Niigata, Japan. [Villacampa G] Oncology Data Science, Vall d’Hebron Institut d'Oncologia (VHIO), Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Oaknin A] Servei d’Oncologia Mèdica, Vall d’Hebron Institut d'Oncologia (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-11-24T10:31:42Z
2025-11-24T10:31:42Z
2025-11
Angiogenesis Inhibitors; Atezolizumab; Bevacizumab
Inhibidores de la angiogénesis; Atezolizumab; Bevacizumab
Inhibidors de l'angiogènesi; Atezolizumab; Bevacizumab
Objective: This study analyzed the efficacy of add-on atezolizumab to standard first-line bevacizumab-containing therapy in 56 Japanese patients with metastatic and recurrent cervical cancer treated across 8 sites under the Japanese Gynecologic Oncology Group between October 2018 and August 2021 in the BEATcc trial. Methods: Patients were randomized to standard arm (standard therapy: cisplatin 50 mg/m² or carboplatin area under the curve of 5, paclitaxel 175 mg/m², and bevacizumab 15 mg/kg) or experimental arm (standard therapy with atezolizumab 1,200 mg). Results: Of 56 patients, 30 were in experimental arm vs. 26, standard arm (age: 53.2±12.9 vs. 54.7±12.2 years). Median progression-free survival was 15.8 months (95% confidence interval [CI]=10.4-26.1) in experimental arm vs. 11.1 months (8.4-16.5) in standard arm (hazard ratio [HR]=0.51; 95% CI=0.26-1.01). Median overall survival was 34.1 months (23.2-38.6) in the experimental arm vs. 31.6 months (16.4-36.5), standard arm (HR=0.53; 95% CI=0.23-1.21). Objective response rate was 86.7% in experimental arm vs. 84.6%, standard arm. Complete response and partial response, respectively, were 23.3% and 63.3% in experimental arm and 26.9% and 57.7% in standard arm. Grade ≥3 adverse events occurred in 80.0%, experimental arm and 88.5%, standard arm. Gastrointestinal/genitourinary fistula incidence was lower in Japanese patients (1 patient receiving atezolizumab), likely due to stricter inclusion criteria. Conclusion: Overall, add-on atezolizumab enhances the efficacy of bevacizumab and chemotherapy in Japanese patients as those in overall BEATcc population and could be considered a new first-line treatment option for metastatic, persistent, or recurrent cervical cancer in Japan. Trial registration: ClinicalTrials.gov Identifier: NCT03556839.
The trial was funded by F. Hoffmann-La Roche AG and Chugai Pharmaceutical Co., Ltd.
Article
Versió publicada
Anglès
Anticossos monoclonals - Ús terapèutic; Quimioteràpia combinada; Platí; Coll uterí - Càncer - Tractament; Avaluació de resultats (Assistència sanitària); DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Female::Uterine Neoplasms::Uterine Cervical Neoplasms; Other subheadings::Other subheadings::Other subheadings::/drug therapy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized; Other subheadings::Other subheadings::/therapeutic use; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome; CHEMICALS AND DRUGS::Inorganic Chemicals::Platinum Compounds; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales femeninos::neoplasias uterinas::neoplasias del cuello uterino; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados; Otros calificadores::Otros calificadores::/uso terapéutico; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento; COMPUESTOS QUÍMICOS Y DROGAS::compuestos inorgánicos::compuestos de platino
Korean Society of Gynecologic Oncology
Journal of Gynecologic Oncology;36(6)
https://doi.org/10.3802/jgo.2025.36.e116
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
Articles científics - HVH [3393]
